Gland Pharma reported a robust start to FY27, with consolidated revenue from operations rising 20% year-on-year to ₹18,003 million in the quarter ended June 30, 2026. Profit after tax (PAT) surged 47% to ₹3,170 million, driven by strong demand in its Contract Development and Manufacturing Operations (CDMO) segment and significant volume expansion in key markets like the United States. The company’s EBITDA margin expanded to 27% from 24% in the corresponding quarter of the previous year, reflecting improved operational efficiency.

The Board of Directors, meeting on August 10, 2026, approved the unaudited standalone and consolidated financial results pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Deloitte Haskins & Sells, the statutory auditors, issued an unmodified limited review report on the financial statements prepared in accordance with Ind AS 34.

Consolidated Financial Performance

Gland Pharma’s top-line growth was supported by equal contributions from its CDMO and B2B businesses, each accounting for 50% of total revenue. The CDMO segment grew 20% YoY to ₹8,915 million, while B2B revenue increased 19% to ₹9,088 million. Adjusted EBITDA, which excludes employee stock option compensation expenses, rose 37% to ₹5,102 million, with an adjusted margin of 28%.

Market and Segment Highlights

The United States remained the largest market, contributing 54% of total revenue with a 32% YoY increase to ₹9,810 million. Growth was fueled by recent product launches, including Dalbavancin and Multi-Vitamin, and volume expansion in existing products such as Enoxaparin and Heparin. Europe saw a 20% revenue rise to ₹3,954 million, driven by CDMO products. Conversely, Other Core Markets (Canada, Australia, New Zealand) declined 28% to ₹534 million due to volume drops in existing products.

Research and development expenses stood at ₹772 million, representing 4% of consolidated revenue. The company launched four new molecules in the USA during the quarter. Regulatory progress included three new Abbreviated New Drug Application (ANDA) filings and seven approvals, bringing the cumulative US ANDA portfolio to 389 filings (342 approved, 47 pending).

Pipeline and Strategic Initiatives

Gland Pharma continues to strengthen its complex injectables pipeline, with six products already launched and three more awaiting approval. Fifteen products are currently in co-development, including seven 505(b)(2) applications and eight ANDAs, with commercialization expected to begin in FY28. The company also filed 21 Ready-to-Use (RTU) infusion bag products, receiving approval for 18 so far; this portfolio addresses an estimated $644 million opportunity in the US market.

Strategic collaborations include a long-term partnership with Neuland Laboratories for sterile API manufacturing of microparticle depot products and an in-licensing agreement with a China-based developer for a niche liposomal product targeting US and European markets. Additionally, a CDMO partnership with a global pharmaceutical company holds an annualized revenue potential of $90–100 million, with revenues expected to commence from calendar year 2029.

What the Numbers Show

The divergence between consolidated PAT growth (47%) and revenue growth (20%) highlights significant operating leverage achieved through scale. While gross profit margins remained stable at 65%, the expansion in EBITDA margins from 24% to 27% indicates effective cost management despite rising employee benefits expenses (up to ₹4,440 million from ₹4,080 million YoY). The strong cash position, with net cash at ₹32,939 million as of June 2026, provides ample liquidity to fund ongoing capital expenditures of ₹1,132 million in Q1FY27 and future pipeline developments.

Gland Pharma has entered into a strategic Manufacturing and Supply Agreement (MSA) with a leading global pharmaceutical company to manufacture and supply a portfolio of sterile injectable products for global markets. The partnership establishes the Hyderabad-based firm as an integrated end-to-end partner, covering technology transfer, process development, scale-up, validation, commercial manufacturing, and long-term supply under a full-service Contract Development and Manufacturing Organization (CDMO) model. This agreement provides significant long-term business visibility, with annualized revenue potential estimated at USD 90–100 million once all products are commercialized.

The filing was made pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Additional details were provided under SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The counterparty's name remains undisclosed due to confidentiality obligations, though it is identified as one of the leading global pharmaceutical companies.

Deal Structure and Product Portfolio

The agreement encompasses a diversified basket of oncology and non-oncology products in Vial, Lyo, Ampoules, and pre-filled syringe (PFS) presentations. These formulations cover both complex and conventional injectable types. Gland Pharma will leverage its integrated capabilities across development, technology transfer, manufacturing, quality, and regulatory support to provide a comprehensive "one-stop" solution. The current scope includes 55 Stock Keeping Units (SKUs) to be manufactured across three sites, with provisions to add more products in the near future.

Timeline and Execution

Technology transfer activities are planned for completion within two years. Revenues from this partnership are anticipated to commence from calendar year 2029. The collaboration supports multiple products across various stages of the product lifecycle, including both commercially marketed products and pipeline products under development. Srinivas Sadu, Executive Chairman of Gland Pharma, stated that the partnership highlights the confidence global pharmaceutical companies place in the company's development, technology transfer, manufacturing, and supply capabilities. He noted that the agreement supports the expansion of the CDMO business and creates a strong foundation for future growth.

What the Numbers Show

The commitment to 55 SKUs across three manufacturing sites indicates a substantial allocation of capacity and resources by Gland Pharma. While the revenue generation is deferred until calendar year 2029, the annualized potential of USD 90–100 million represents a significant addition to the company's top-line visibility. The inclusion of both oncology and non-oncology products in complex presentations like pre-filled syringes suggests a focus on high-value, technically demanding formulations rather than conventional low-margin generics. This diversification within the sterile injectables segment aligns with the company's strategy to deepen its integration as a full-service CDMO partner.